Lung cancer
Conditions
Interventions
three-hole thoracoscopic group:Three-port thoracoscopic for surgery
single-hole thoracoscopic surgery group:Single port thoracoscopy for surgery
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Preoperative clinical diagnosis of patients with stage I and II lung cancer; staging refers to the eighth edition of the International Association for the Study of Lung Cancer (IASLC, International Association for the Study of Lung Cancer) lung cancer staging. (2) Aged 18 - 75 years; (3) ECOG physical strength status score is 0 or 1; (4) The preoperative ASA anesthesia score is I to III; (5) Hematology, liver and kidney function are normal, and heart and lung function tests indicate that surgery can be tolerated; (6) Preoperative chest CT and other examinations showed that the diameter of the tumor was =5cm, and there was no pleura and distant metastasis; (7) No radiotherapy or chemotherapy was received before surgery; (8) Postoperative pathological diagnosis of non-small cell lung cancer; staging refer to the International Association for the Study of Lung Cancer (IASLC, International Association for the Study of Lung Cancer) eighth edition lung cancer staging. (9) Able to understand and follow the research and follow-up procedures, and sign an informed consent to participate in this research.
Exclusion criteria
Exclusion criteria: (1) Those who have a history of other malignant tumors in the past or the same period; (2) Distant metastases are found before surgery; (3) Severe organic diseases, including active infections, cardiovascular diseases or blood system diseases, etc.; (4) Pregnant or lactating women; (5) Cardiopulmonary reserve cannot tolerate surgery; (6) Preoperative chest CT showed that the diameter of the tumor was greater than 5 cm, and the thoracic cavity had extensive pleural adhesions; (7) Those who have received chemotherapy and/or radiotherapy before surgery; (8) Poor compliance, unable to follow the research and follow-up procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;complication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;operation time;Intraoperative blood loss;The ratio of transfer to open chest;The number and number of lymph node dissection groups;Chest tube indwelling time;Postoperative chest tube drainage,;Postoperative pain degree;length of hospital stay.; | — |
Countries
China
Contacts
Public ContactLiang Zhu
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed